scPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.44 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -13.33%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.34, delivering a surprise of -25.93%. Over the last four quarters, the company ...

公司业绩表现 - 季度每股收益为0.02美元，低于市场预期的0.05美元，同比去年0.03美元下降[1] - 季度营收达5.2115亿美元，超出市场预期11.24%，同比去年4.2233亿美元增长[2] - 过去四个季度均未达到每股收益预期，但四次营收均超预期[2] 市场反应与股价 - 本季度盈利意外为-60%，上一季度为-50%[1] - 年初至今股价上涨1.2%，同期标普500指数上涨7.9%[3] - 当前Zacks评级为3级（持有），预计短期表现与市场持平[6] 未来展望 - 下季度预期每股收益0.07美元，营收4.7401亿美元[7] - 当前财年预期每股收益0.21美元，营收19.1亿美元[7] - 盈利预测修订趋势近期呈现混合状态[6] 行业比较 - 所属医疗信息系统行业在Zacks行业排名中位列前37%[8] - 同业公司Nyxoah SA预计季度每股亏损0.62美元，同比恶化34.8%，营收预期173万美元同比增长108%[9]